Per a court order, HHS is required to restore this website to its version as of 12:00 AM on January 29, 2025. Information on this page may be modified and/or removed in the future subject to the terms of the court’s order and implemented consistent with applicable law. Any information on this page promoting gender ideology is extremely inaccurate and disconnected from truth. The Trump Administration rejects gender ideology due to the harms and divisiveness it causes. This page does not reflect reality and therefore the Administration and this Department reject it.

U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Opioid Antagonists for Alcohol Dependence

About this resource:

Systematic Review

Source: The Cochrane Collaborative

Last Reviewed: December 2010

Workgroups: Substance Use Workgroup

In this Cochrane systematic review, the Cochrane Collaborative found that the opioid antagonist naltrexone can help people with alcohol dependence drink less alcohol and drink less often. While naltrexone does not cause serious side effects, it can cause problems like nausea, stomach pain, loss of appetite, and sleepiness. Researchers found that there’s not enough evidence to determine if injectable naltrexone or the opioid antagonist nalmefene is effective in treating alcohol dependence.

Read more about this resource

Objectives related to this resource (1)

Reduce the proportion of people who had alcohol use disorder in the past year — SU‑13
Little or no detectable change

Suggested Citation

1.

Rösner, S., Hackl‐Herrwerth, A., Leucht, S., Vecchi, S., Srisurapanont, M. & Soyka, M. (2010). Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews, 2010 (12). DOI: 10.1002/14651858.CD001867.pub3.